EGFR and cancer: For example, ciRS-7 activates the oncogenes EGFR and RAF1, thereby activating the EGFR/RAF1/MAPK pathway and promoting progression of CRCs, by sponging and suppressing miR-7 activity (8); while circHAS2 activates CCNE2 by sponging miR-1244 to enhance cell proliferation and sensitivity of CRC to anlotinib, a multi-target TKI used to treat cancers (9).